Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475 versus chemotherapy in advanced melanoma
2012-003030-17Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2012
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of pembrolizumab in melanoma (2 arms), sponsored by Merck & Co. Primary endpoints: Overall response rate by Week 12, Progression-free survival and 1 more. Started Oct 2012; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2012-003030-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003030-17.